Search

for
Search:

Research

5 / 1000+ results

research Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers

August 2026 in “Frontiers in Medicine”

This review discusses the potential applications of JAK inhibitors in various dermatological conditions beyond atopic dermatitis, emphasizing gaps in evidence and therapeutic opportunities in the context of Chinese clinical practice, but reports no new clinical results.

research 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse

1 citations , November 2023 in “Journal of Investigative Dermatology”

Farudodstat may effectively treat alopecia areata without harming hair follicles.

research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier

4 citations , December 2024 in “European Journal of Medicinal Chemistry”

This study reported the development of new pyrazole-based MPC inhibitors that effectively inhibit mitochondrial pyruvate transport, showing potential as therapeutic candidates for conditions like metabolic dysfunction-associated steatohepatitis without activating PPARγ.

research Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report

April 2023 in “Revista colombiana de reumatología”

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso

August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia”

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

View more "therapeutic inhibitors" in research →

Community Join

5 / 153 results

community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia

in Research/Science 13 upvotes 1 year ago

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

community Minoxidil inhibits lysyl hydroxylase which is needed to produce collagen. If I take 2,5...5 mg of minoxidil every day can I cause my skin to age prematurely?

32 upvotes 1 year ago

Oral minoxidil is effective for hair loss and unlikely to significantly affect collagen synthesis, making it a safe option without causing premature skin aging. Users report positive hair regrowth without noticeable skin aging.

community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results

in Update 415 upvotes 1 year ago

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

community Androsterone as a Neurosteroid Replacement Strategy for 5α-Reductase Inhibitor–Associated Sexual and Affective Dysfunction

in Research/Science 36 upvotes 2 months ago

Androsterone may help with sexual and affective dysfunction from finasteride by replacing disrupted neurosteroids without increasing androgenic side effects. Controlled testing is needed to confirm its effectiveness and safety.

community How come Dut doesn’t cause more brain problems than fin if it inhibits Type 1 5AR?

in Finasteride/Dutasteride 22 upvotes 2 years ago

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

View more "therapeutic inhibitors" in community →